Who makes SB-525 (PF-07055480)?

SB-525 (PF-07055480) is developed by Pfizer Inc..

What development phase is SB-525 (PF-07055480) in?

SB-525 (PF-07055480) is in Phase 2.

What are the side effects of SB-525 (PF-07055480)?

Common side effects include Upper respiratory tract infection, Alanine aminotransferase increased, Aspartate aminotransferase increased, Splenomegaly, Food poisoning, Hepatic steatosis.

What is the generic name of SB-525 (PF-07055480)?

sb-525-pf-07055480 is the generic (nonproprietary) name of SB-525 (PF-07055480).

Last reviewed 2026-04-20 · How we verify

SB-525 (PF-07055480) (sb-525-pf-07055480)

Pfizer Inc. · Phase 2 active Quality 15/100

At a glance

Generic name	sb-525-pf-07055480
Sponsor	Pfizer Inc.
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

Upper respiratory tract infection
Alanine aminotransferase increased
Aspartate aminotransferase increased
Splenomegaly
Food poisoning
Hepatic steatosis
Urinary tract infection
Skin laceration
Wound
Eosinophil count increased
SARS-CoV-2 test positive
Hyperuricaemia

Key clinical trials

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A (PHASE2)
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB-525 (PF-07055480) CI brief — competitive landscape report
SB-525 (PF-07055480) updates RSS · CI watch RSS
Pfizer Inc. portfolio CI